XERS Q4 2021 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+202.1% YoY

Gross Profit

$17M77.4% margin

Operating Income

-$48M-222.8% margin

Net Income

-$51M-234.4% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+96.4%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$304M

Total Liabilities

$209M

Stockholders' Equity

$95M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$7M	+202.1%
Gross Profit	$17M	$4M	+345.7%
Operating Income	-$48M	-$19M	-149.6%
Net Income	-$51M	-$22M	-132.4%